Haihe Biopharma Co. Ltd. has published work on the discovery of novel ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) inhibitors being developed for the treatment of cancer.

Researchers from Shanghai Institute of Biological Products Co. Ltd. published details on the development and preclinical characterization of novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, referred to as tandem antigen-binding fragment 002 (TFAB-002).

Protein homeostasis is disrupted in response to an uncontrolled stress condition, a hallmark of many diseases, such as cataracts. Lens protein accumulation and aggregates are a cause of cataract development.

Researchers from Proqr Therapeutics NV recently presented preclinical data on AX-0810, a single-stranded RNA editing oligonucleotide (EON) targeting RNA coding for NTCP cotransporter

Marvel Biosciences Corp. and its wholly owned subsidiary Marvel Biotechnology Inc. have reported promising results from a recent study of MB-204 in the Oprm1 mouse model of autism, showing that just 1 hour after administering a single oral dose of MB-204, the drug successfully reversed the social behavior deficits typically seen in the model.

Recent evidence has suggested CDGSH iron-sulfur domain-containing protein 3 (CISD3) plays a tumorigenic role and is a key member in mitochondrial functioning. Additionally, the methylation changes surrounding the CISD3 gene plus its expression patterns in several cancer types suggest its potential as a biomarker and therapeutic target.

Breast cancer cells, when disseminated to other secondary organs such as the lungs, may stay in a dormant state for years, even decades. But the mechanisms that limit their expansion are not well understood. This is what researchers call a dormant mesenchymal-like phenotype (M-like) before metastasis to the lungs. Now, scientists have shown in a study published Oct. 7, 2024, in Cell, that the limiting of disseminated breast cancer cells (DCCs) to metastasize in the lungs is due to alveolar macrophages (AMs), which activate signals that make DCCs stay dormant.

Booster Therapeutics is ready to open up a new arm of the proteasome after raising $15 million in seed funding to advance small molecules it says can degrade multiple types of harmful proteins. Rather than tagging single disease proteins with a ubiquitin marker for degrading via 26S proteasomes, these compounds directly activate 20S proteasomes that naturally recognize disordered proteins without the need for ubiquitin tagging.